20 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein.
Mirati Therapeutics
Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography.
Mirati Therapeutics
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.
Mirati Therapeutics
Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors.
Mirati Therapeutics
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of
Mirati Therapeutics
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS
Mirati Therapeutics
Chemical Compounds Useful for Inhibiting Nav1.8 Voltage-Gated Sodium Channels and Treating Nav1.8 Mediated Diseases
Glaxosmithkline Intellectual Property Development
Hetero ring-fused phenyl compounds for inhibiting TNIK and medical uses thereof
Korea Research Institute of Chemical Technology
Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease
Shy Therapeutics
N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
Kalvista Pharmaceuticals
Carbonic anhydrases inhibitory effects of new benzenesulfonamides synthesized by using superacid chemistry.
Laboratoire Synthese Et Reactivite Des Substances Naturelles
Unusual activity pattern of leucine aminopeptidase inhibitors based on phosphorus containing derivatives of methionine and norleucine.
Academy of Sciences of The Czech Republic